Toxic Epidermal Necrolysis Inducided by Lamotrigine. Treatment with Intravenous Immunoglobulins;Necrólisis Epidérmica Tóxica Inducida por Lamotrigina. Tratamiento con Inmunoglobulina Intravenosa

Medicina Cutanea Ibero-Latino-Americana

Volumn 31, Issue 3, 2003, Pages 182-186

  Gatti, Carlos Fernando ^a,b   Rodríguez, María Clara ^a   Cha, Diana Marta ^a   Barquín, María Antonia ^a  

^a Unidad Asistencial Dr César Milstein   (Argentina)

^b NONE   (Argentina)

Author keywords

Anticonvulsants; Intravenous immunoglobulins triazines; Lamotrigine; Toxic epidermal necrolysis

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CARBAMAZEPINE; CEFTAZIDIME; CLONAZEPAM; IMIPENEM; IMMUNOGLOBULIN; LAMOTRIGINE; PSEUDOMONIC ACID; TRIAZINE DERIVATIVE; VALPROIC ACID; VANCOMYCIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; PATHOGENESIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

EID: 0142058162     PISSN: 02105187     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schulz JT, Sheridan RL, Ryan CM, Mc Kool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204.
2. Rougeau JC, Kelly JP, Naldi L, et al. Medicación use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
3. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000;18:485-95,ix.
4. Bastuji-Garin S, Rzany, B Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993;129: 92-6.
5. Bastuji-Garin S, Fouchard N, Bertocci M, Roujeau JC, et al. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
6. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive-Care-Med. 1997;23:1237-44.
7. García Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323-7.
8. Palomo A, Rodriguez Gómez J, Guerrero E. Necrólisis epidérmica tóxica inducida por lamotrigina. Tratamiento con ciclosporina. Actas Dermosifilogr 1999;90:612-615.
9. Bushman M, Brooke R, Hewitt-Symonds, M. Prolonged toxic epidermal necrolysis due to Lamotrigine. Clin. Exp. Dermatol. 2000;25: 349-51.
10. Bocquet H, Farmer M, Bresieux JM. Lyell syndrome and Stevens-Johnson syndrome caused by lamotrigine. Ann-dermatol-venerol. 1999;126:46-8.
11. Duval X, Chosidow O, Semah F, Lipsker D. Lamotrigine versus carbamazepine in epilepsy. Lancet 1995;345:1301-2.
12. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998;39(Suppl 7):S22-6.
13. Vukelic D, Bozinovic D, Tesovic G. Lamotrigine and toxic epidermal necrolysis. Dermatology. 1997;195:307.
14. Rzanny B, Correia O, Kelly JP. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study group of the international case control study on severe cutaneous adverse reactions. Lancet 1999;353:2190-4.
15. Sullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and inmunosupressive management. Australas J Dermatol. 1996;37: 208-12.
16. Stella M, Cassano P, Bollero D, Clemente A. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001;203:45-9.
17. Leyva L, Torres MJ, Posadas S. Anticonvulsant-induced toxic epidermal necrolysis: monitoring the inmunologic response. J Allergy Clin Inmunol 2000; 105(1 Pt 1): 157-65.
18. Egan CA, Grant WJ, Morris SE. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40: 458-61.
19. Viard I, Wehrli P, Bullan R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-3.
20. French. Inhibición de la necrótisis epidérmica tóxica con Ig G intravenosa humana. Act Terap Dermatol 2000;23:369.
21. Trent Jt, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the university of Miami experience. Arch Dermatol. 2003;139:39-43.
22. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139: 33-6.
23. Magina S, Lisboa C, Goncalves E, Conceicao F. A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. Br J Dermatol 2000;142:191-2.
24. Rutter A, Luger TA. High-dose intravenous immunoglobulin: an approach to treat severe immune-mediated and autoimmune disease of the skin. J Am Acad Dermatol. 2001;44: 1010-24.
25. Dahl MV, Bridges Ag. Intravenous immune globulin: Fighting antibodies with antibodies. J Am Acad Dermatol. 2001;45:775-83.
26. Power WJ, Ghoraishi M, Merayo-Lloves J, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/ Stevens-Johnson syndrome / toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102:1669-76.